Evidence map›Paper›PMID 38386085›Full record

ArticleActa neuropathologica2024

MET receptor serves as a promising target in melanoma brain metastases.

Torben Redmer, Elisa Schumann, Kristin Peters, Martin E Weidemeier, Stephan Nowak, Henry W S Schroeder, Anna Vidal, Helena Radbruch, Annika Lehmann, Susanne Kreuzer-Redmer and 2 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Genetic and immune landscape of keratoconus: insights from Mendelian randomization analysis.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Torben RedmerInstitute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria. torben.redmer@vetmeduni.ac.at.ORCID 0000-0002-0050-9478
Elisa SchumannDepartment of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Kristin PetersInstitute of Pathology, University Medicine Greifswald, Greifswald, Germany.
Martin E WeidemeierDepartment of Neurosurgery, University Medicine Greifswald, Greifswald, Germany.
Stephan NowakDepartment of Neurosurgery, University Medicine Greifswald, Greifswald, Germany.
Henry W S SchroederDepartment of Neurosurgery, University Medicine Greifswald, Greifswald, Germany.
Anna VidalInstitute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria.
Helena RadbruchDepartment of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Annika LehmannInstitute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Susanne Kreuzer-RedmerNutrigenomics Unit, Institute of Animal Nutrition and Functional Plant Compounds, University of Veterinary Medicine Vienna, Vienna, Austria.
Karsten JürchottCenter for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Josefine RadkeInstitute of Pathology, University Medicine Greifswald, Greifswald, Germany. josefine.radke@med.uni-greifswald.de.
Universitätsmedizin Greifswald · DEHumboldt-Universität zu Berlin · DEUniversity of Veterinary Medicine Vienna · ATBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of brain metastases hallmarks disease progression in 20-40% of melanoma patients and is a serious obstacle to therapy. Understanding the processes involved in the development and maintenance of melanoma brain metastases (MBM) is critical for the discovery of novel therapeutic strategies. Here, we generated transcriptome and methylome profiles of MBM showing high or low abundance of infiltrated Iba1

Indexed as

Brain NeoplasmsMelanomaDisease ProgressionHumansInterferonsProto-Oncogene Proteins B-rafInterferonsProto-Oncogene Proteins B-rafBrain metastasisInterferon signalingITGB7MelanomaMET receptorTAMs

Identifiers

PMID38386085
PMCPMC10884227
OpenAlexW4392080264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.